82 filings
Page 3 of 5
8-K
07fiq2i vr5xyr
28 May 21
Submission of Matters to a Vote of Security Holders
9:05am
8-K
eoyvktb
13 May 21
Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update
4:13pm
8-K
hdw4jqddeai6 kmb
30 Mar 21
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients
4:52pm
8-K
e9b7nnbl4up3035n8rq
24 Mar 21
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update
4:10pm
8-K
1s8xpwe8x
15 Mar 21
Regulation FD Disclosure
8:02am
8-K
lu4n947 ebhb
9 Mar 21
Regulation FD Disclosure
7:00am
8-K
w4mfc0q6z4r05g0 9j8
12 Feb 21
Regulation FD Disclosure
3:05pm
8-K
n1njw3ok3y5ovk7nj
4 Feb 21
Equillium Announces Pricing of $30 Million Registered Direct Offering
8:10am
8-K
hu6umqn1kq
21 Dec 20
Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of
8:06am
8-K
acrioahdh
7 Dec 20
Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell
9:24am
8-K
d19esr
4 Dec 20
Regulation FD Disclosure
9:07am
8-K
mrzxmr1oibniig s1p
30 Nov 20
Regulation FD Disclosure
8:01am
8-K
peao6o2bb26qczl4qzp
25 Nov 20
Equillium Provides Itolizumab COVID-19 Program Update
8:01am
8-K
2shimj 7f7ru5
10 Nov 20
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
4:11pm
8-K
lur1it
29 Oct 20
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
5:12pm
8-K
zqkl8qxi7axg78v5tv
28 Sep 20
Departure of Directors or Certain Officers
5:00pm
8-K
6d496p4d
14 Aug 20
Equillium Announces Proposed Public Offering of Common Stock
4:50pm
8-K
3qvphz9s5ikegvd0 oi
12 Aug 20
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
8:40am
8-K
6jrwx28gyr412ksg
10 Aug 20
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
5:21pm
8-K
h3tnxhe14mn
14 Jul 20
Entry into a Material Definitive Agreement
6:08am